Your browser doesn't support javascript.
loading
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
Baggen, Jim; Jacquemyn, Maarten; Persoons, Leentje; Vanstreels, Els; Pye, Valerie E; Wrobel, Antoni G; Calvaresi, Valeria; Martin, Stephen R; Roustan, Chloë; Cronin, Nora B; Reading, Eamonn; Thibaut, Hendrik Jan; Vercruysse, Thomas; Maes, Piet; De Smet, Frederik; Yee, Angie; Nivitchanyong, Toey; Roell, Marina; Franco-Hernandez, Natalia; Rhinn, Herve; Mamchak, Alusha Andre; Ah Young-Chapon, Maxime; Brown, Eric; Cherepanov, Peter; Daelemans, Dirk.
Afiliación
  • Baggen J; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium. Electronic address: jim.baggen@kuleuven.be.
  • Jacquemyn M; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium.
  • Persoons L; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium.
  • Vanstreels E; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium.
  • Pye VE; Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  • Wrobel AG; Structural Biology of Disease Processes Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  • Calvaresi V; Department of Chemistry, Britannia House, 7 Trinity Street, King's College London, London SE1 1DB, UK.
  • Martin SR; Structural Biology of Disease Processes Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  • Roustan C; Structural Biology Science Technology Platform, Francis Crick Institute, London NW1 1AT, UK.
  • Cronin NB; LonCEM Facility, Francis Crick Institute, London NW1 1AT, UK.
  • Reading E; Department of Chemistry, Britannia House, 7 Trinity Street, King's College London, London SE1 1DB, UK.
  • Thibaut HJ; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium.
  • Vercruysse T; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium.
  • Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, Leuven 3000, Belgium.
  • De Smet F; KU Leuven Department of Imaging and Pathology, Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Leuven 3000, Belgium.
  • Yee A; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Nivitchanyong T; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Roell M; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Franco-Hernandez N; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Rhinn H; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Mamchak AA; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Ah Young-Chapon M; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Brown E; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA.
  • Cherepanov P; Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, Section of Virology, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. Electronic address: peter.cherepanov@crick.ac.uk.
  • Daelemans D; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium. Electronic address: dirk.daelemans@kuleuven.be.
Cell ; 186(16): 3427-3442.e22, 2023 08 03.
Article en En | MEDLINE | ID: mdl-37421949
ABSTRACT
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal transmembrane protein, can serve as an alternative receptor for SARS-CoV-2 entry into angiotensin-converting enzyme 2 (ACE2)-negative cells. Spike substitution E484D increased TMEM106B binding, thereby enhancing TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies blocked SARS-CoV-2 infection, demonstrating a role of TMEM106B in viral entry. Using X-ray crystallography, cryogenic electron microscopy (cryo-EM), and hydrogen-deuterium exchange mass spectrometry (HDX-MS), we show that the luminal domain (LD) of TMEM106B engages the receptor-binding motif of SARS-CoV-2 spike. Finally, we show that TMEM106B promotes spike-mediated syncytium formation, suggesting a role of TMEM106B in viral fusion. Together, our findings identify an ACE2-independent SARS-CoV-2 infection mechanism that involves cooperative interactions with the receptors heparan sulfate and TMEM106B.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Año: 2023 Tipo del documento: Article